\u674f\u6797\u88fd\u85ac<\/a> \u306f\u65e5\u672c\u306b\u304a\u3051\u308b\u8cc7\u91d1\u8abf\u9054\u3068\u958b\u767a\u3092\u7ba1\u7406\u3057\u307e\u3059\u3002\u307e\u305f\u3001\u85ac\u4e8b\u3001\u30de\u30fc\u30b1\u30c6\u30a3\u30f3\u30b0\u3001\u5546\u54c1\u5316\u3082\u62c5\u5f53\u3057\u307e\u3059\u3002\u307e\u305f\u3001\u30b0\u30ed\u30fc\u30d0\u30eb\u958b\u767a\u306b\u3082\u5354\u529b\u3057\u307e\u3059\u3002\u5171\u540c\u904b\u55b6\u59d4\u54e1\u4f1a\uff08JSC\uff09\u304c\u8a2d\u7acb\u3055\u308c\u307e\u3057\u305f\u3002JSC\u306f\u3001\u69d8\u3005\u306aB\u7d30\u80de\u4ecb\u5728\u6027\u81ea\u5df1\u514d\u75ab\u75be\u60a3\u3092\u5bfe\u8c61\u3068\u3059\u308b\u30d7\u30ed\u30b0\u30e9\u30e0\u3092\u6307\u5c0e\u3057\u3001\u62e1\u5927\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002<\/p>","protected":false},"excerpt":{"rendered":"Hinge Bio, Inc., a private biotech firm that focuses on multispecific antibody medicines, announced a partnership with Kyorin Pharmaceutical Co., Ltd. They also signed a licensing deal. Kyorin is developing and selling HB2198 in Japan. It targets multiple autoimmune conditions, starting with Systemic Lupus Erythematosus (SLE). Also Read: Celaid Therapeutics and AGC sign iPSC-HSPC research deal Hinge Bio will get a US$ 10 million upfront payment. They can also earn up to US$ 95 million in milestone payments for the SLE indication. Plus, there are more milestone payments for future indications. Hinge Bio will lead the global development of HB2198. Kyorin Pharmaceutical will manage funding and development in Japan. They […]<\/p>\n","protected":false},"author":7,"featured_media":21958,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[208,181,89,211,237,206],"tags":[3503,8235,8236,7320,8234],"ppma_author":[572],"class_list":{"0":"post-21957","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-apac","8":"category-biotech","9":"category-health-tech","10":"category-japan","11":"category-news","12":"category-regional","13":"tag-biotechnology","14":"tag-hb2198","15":"tag-hinge-bio","16":"tag-kyorin-pharmaceutical","17":"tag-systemic-lupus-erythematosus"},"yoast_head":"\n
Hinge Bio Licenses HB2198 to Kyorin for Autoimmune Use<\/title>\n<meta name=\"description\" content=\"Hinge Bio partners with Kyorin to develop and commercialize HB2198 in Japan, targeting autoimmune diseases starting with SLE.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/biotech\/hinge-bio-partners-with-kyorin-to-develop-hb2198-in-japan\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hinge Bio Licenses HB2198 to Kyorin for Autoimmune Use\" \/>\n<meta property=\"og:description\" content=\"Hinge Bio partners with Kyorin to develop and commercialize HB2198 in Japan, targeting autoimmune diseases starting with SLE.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/biotech\/hinge-bio-partners-with-kyorin-to-develop-hb2198-in-japan\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-01T12:13:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/10\/Hinge-Bio-Announces-License-and-Collaboration-with-Kyorin-Pharmaceutical-Co._-Ltd.-for-the-Development-and-Commercialization-of-HB2198-in-Japan-for-Autoimmune-Diseases.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"ITBT StaffWriter\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ITBT StaffWriter\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30d2\u30f3\u30b8\u30fb\u30d0\u30a4\u30aa\u793e\u3001HB2198\u3092\u30ad\u30e7\u30fc\u30ea\u30f3\u88fd\u85ac\u306b\u81ea\u5df1\u514d\u75ab\u7528\u9014\u3067\u5c0e\u51fa","description":"\u30d2\u30f3\u30b8\u30fb\u30d0\u30a4\u30aa\u306f\u30ad\u30e7\u30fc\u30ea\u30f3\u88fd\u85ac\u3068\u63d0\u643a\u3057\u3001SLE\u3092\u306f\u3058\u3081\u3068\u3059\u308b\u81ea\u5df1\u514d\u75ab\u75be\u60a3\u3092\u30bf\u30fc\u30b2\u30c3\u30c8\u3068\u3057\u305fHB2198\u3092\u65e5\u672c\u3067\u958b\u767a\u30fb\u5546\u696d\u5316\u3057\u307e\u3059\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/biotech\/hinge-bio-partners-with-kyorin-to-develop-hb2198-in-japan\/","og_locale":"ja_JP","og_type":"article","og_title":"Hinge Bio Licenses HB2198 to Kyorin for Autoimmune Use","og_description":"Hinge Bio partners with Kyorin to develop and commercialize HB2198 in Japan, targeting autoimmune diseases starting with SLE.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/biotech\/hinge-bio-partners-with-kyorin-to-develop-hb2198-in-japan\/","og_site_name":"itbusinesstoday","article_published_time":"2025-10-01T12:13:26+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/10\/Hinge-Bio-Announces-License-and-Collaboration-with-Kyorin-Pharmaceutical-Co._-Ltd.-for-the-Development-and-Commercialization-of-HB2198-in-Japan-for-Autoimmune-Diseases.webp","type":"image\/webp"}],"author":"ITBT StaffWriter","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"ITBT StaffWriter","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"1\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/hinge-bio-partners-with-kyorin-to-develop-hb2198-in-japan\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/hinge-bio-partners-with-kyorin-to-develop-hb2198-in-japan\/"},"author":{"name":"ITBT StaffWriter","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15"},"headline":"Hinge Bio partners with Kyorin to Develop HB2198 in Japan","datePublished":"2025-10-01T12:13:26+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/hinge-bio-partners-with-kyorin-to-develop-hb2198-in-japan\/"},"wordCount":156,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/hinge-bio-partners-with-kyorin-to-develop-hb2198-in-japan\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/10\/Hinge-Bio-Announces-License-and-Collaboration-with-Kyorin-Pharmaceutical-Co._-Ltd.-for-the-Development-and-Commercialization-of-HB2198-in-Japan-for-Autoimmune-Diseases.webp","keywords":["Biotechnology","HB2198","Hinge Bio","Kyorin Pharmaceutical","Systemic Lupus Erythematosus"],"articleSection":["APAC","Biotech","Health Tech","Japan","News","Regional"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/hinge-bio-partners-with-kyorin-to-develop-hb2198-in-japan\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/hinge-bio-partners-with-kyorin-to-develop-hb2198-in-japan\/","name":"\u30d2\u30f3\u30b8\u30fb\u30d0\u30a4\u30aa\u793e\u3001HB2198\u3092\u30ad\u30e7\u30fc\u30ea\u30f3\u88fd\u85ac\u306b\u81ea\u5df1\u514d\u75ab\u7528\u9014\u3067\u5c0e\u51fa","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/hinge-bio-partners-with-kyorin-to-develop-hb2198-in-japan\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/hinge-bio-partners-with-kyorin-to-develop-hb2198-in-japan\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/10\/Hinge-Bio-Announces-License-and-Collaboration-with-Kyorin-Pharmaceutical-Co._-Ltd.-for-the-Development-and-Commercialization-of-HB2198-in-Japan-for-Autoimmune-Diseases.webp","datePublished":"2025-10-01T12:13:26+00:00","description":"\u30d2\u30f3\u30b8\u30fb\u30d0\u30a4\u30aa\u306f\u30ad\u30e7\u30fc\u30ea\u30f3\u88fd\u85ac\u3068\u63d0\u643a\u3057\u3001SLE\u3092\u306f\u3058\u3081\u3068\u3059\u308b\u81ea\u5df1\u514d\u75ab\u75be\u60a3\u3092\u30bf\u30fc\u30b2\u30c3\u30c8\u3068\u3057\u305fHB2198\u3092\u65e5\u672c\u3067\u958b\u767a\u30fb\u5546\u696d\u5316\u3057\u307e\u3059\u3002.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/hinge-bio-partners-with-kyorin-to-develop-hb2198-in-japan\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/biotech\/hinge-bio-partners-with-kyorin-to-develop-hb2198-in-japan\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/hinge-bio-partners-with-kyorin-to-develop-hb2198-in-japan\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/10\/Hinge-Bio-Announces-License-and-Collaboration-with-Kyorin-Pharmaceutical-Co._-Ltd.-for-the-Development-and-Commercialization-of-HB2198-in-Japan-for-Autoimmune-Diseases.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/10\/Hinge-Bio-Announces-License-and-Collaboration-with-Kyorin-Pharmaceutical-Co._-Ltd.-for-the-Development-and-Commercialization-of-HB2198-in-Japan-for-Autoimmune-Diseases.webp","width":1200,"height":800,"caption":"Hinge Bio"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/biotech\/hinge-bio-partners-with-kyorin-to-develop-hb2198-in-japan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Hinge Bio partners with Kyorin to Develop HB2198 in Japan"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15","name":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png90b3cb23d1d9c08733d969d29ea2d30d","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","caption":"ITBT StaffWriter"},"description":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc\u306f\u3001IT Business Today\u306e\u793e\u5185\u5bc4\u7a3f\u8005\u3067\u3001\u30bf\u30a4\u30e0\u30ea\u30fc\u306a\u30cb\u30e5\u30fc\u30b9\u3068QuickBytes\u306e\u914d\u4fe1\u3092\u62c5\u5f53\u3057\u3066\u3044\u307e\u3059\u3002IT\u3001\u30cf\u30a4\u30c6\u30af\u3001\u4f01\u696d\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u6700\u65b0\u52d5\u5411\u3092\u30ab\u30d0\u30fc\u3057\u3001\u7c21\u6f54\u3067\u30a4\u30f3\u30d1\u30af\u30c8\u306e\u3042\u308b\u6700\u65b0\u60c5\u5831\u3092\u8aad\u8005\u306b\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002","sameAs":["https:\/\/itbusinesstoday.com\/"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/itbt-staffwriter\/"}]}},"authors":[{"term_id":572,"user_id":7,"is_guest":0,"slug":"itbt-staffwriter","display_name":"ITBT StaffWriter","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/21957","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=21957"}],"version-history":[{"count":2,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/21957\/revisions"}],"predecessor-version":[{"id":21986,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/21957\/revisions\/21986"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/21958"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=21957"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=21957"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=21957"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=21957"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}